Impax Laboratories Inc. (NASDAQ:IPXL) is engaged in the development, manufacture and marketing of generic (72% of revenue) and branded pharmaceuticals (28%). Impax has 44 ANDAs at the FDA and is developing another 25 generic products. In the branded area, the company had licensed Zomig (migraines) from AstraZeneca (NYSE:AZN) in February 2012. It was a strategic move that brought the company significant revenue and enabled the company to build sales and infrastructure for the marketing of Rytary, a long-acting reformulation of levodopa (a dopamine precursor) for treating Parkinson's Disease, currently awaiting approval. Rytary would be an important incremental advance in the treatment of Parkinson's since it would have reduced the "on-off" periods of regular levodopa. Rytary is...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|